Share on StockTwits

AstraZeneca plc (NYSE:AZN)‘s stock had its “hold” rating reaffirmed by stock analysts at Beaufort Securities in a report issued on Tuesday.

Other equities research analysts have also recently issued reports about the stock. Analysts at Danske upgraded shares of AstraZeneca plc to a “hold” rating in a research note on Tuesday. Separately, analysts at Prime Wealth reiterated a “buy” rating on shares of AstraZeneca plc in a research note on Monday. Finally, analysts at Panmure Gordon downgraded shares of AstraZeneca plc from a “buy” rating to a “hold” rating in a research note on Monday. Three equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $64.50.

Shares of AstraZeneca plc (NYSE:AZN) traded up 2.21% on Tuesday, hitting $72.20. 12,189,454 shares of the company’s stock traded hands. AstraZeneca plc has a 52-week low of $46.87 and a 52-week high of $82.68. The stock’s 50-day moving average is $71.18 and its 200-day moving average is $63.64. The company has a market cap of $91.044 billion and a P/E ratio of 43.31. AstraZeneca plc also saw some unusual options trading activity on Monday. Investors purchased 73,299 call options on the stock. This is an increase of approximately 426% compared to the typical volume of 13,940 call options.

AstraZeneca plc (NYSE:AZN) last announced its earnings results on Thursday, April 24th. The company reported $1.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.23 by $0.06. The company had revenue of $6.42 billion for the quarter, compared to the consensus estimate of $6.32 billion. During the same quarter in the previous year, the company posted $1.41 earnings per share. The company’s revenue for the quarter was up .5% on a year-over-year basis. On average, analysts predict that AstraZeneca plc will post $4.23 earnings per share for the current fiscal year.

AstraZeneca PLC (NYSE:AZN) is a global biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.